These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 80268)

  • 21. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
    Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.
    Momparier RL; Gonzales FA
    Cancer Res; 1978 Sep; 38(9):2673-8. PubMed ID: 79443
    [No Abstract]   [Full Text] [Related]  

  • 24. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.
    Terse P; Engelke K; Chan K; Ling Y; Sharpnack D; Saunthararajah Y; Covey JM
    Int J Toxicol; 2014; 33(2):75-85. PubMed ID: 24639139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
    Jekunen A; Vilpo JA
    J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
    Chiuten DF; Muggia FM; Johnson RK
    Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
    Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
    Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
    Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
    Heby O; Russell DH
    Cancer Res; 1973 Jan; 33(1):159-65. PubMed ID: 4118428
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
    Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T 1/2 clone 8 and V79 cells.
    Landolph JR; Jones PA
    Cancer Res; 1982 Mar; 42(3):817-23. PubMed ID: 6174215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of 5-azacytidine and dihydro-5-azacytidine on nuclear ribosomal RNA and poly(A) RNA synthesis in L1210 cells in vitro.
    Glazer RI; Peale AL; Beisler JA; Abbasi MM
    Mol Pharmacol; 1980 Jan; 17(1):111-7. PubMed ID: 6155602
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Possibilities for the clinical use of 5-azacytidine].
    Veselý J; Cihák A
    Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
    Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
    Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
    Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
    Sirotnak FM; Poser RE; Barrueco JR
    Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.